RC98
Sponsors
RemeGen Co., Ltd.
Conditions
Gastric CancerSolid Tumors
Phase 1
A Study of RC98 in Subjects With Advanced Malignant Solid Tumors
NCT04190823
Start: 2020-03-15End: 2023-12-30Updated: 2023-11-27
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
NCT05514158
Start: 2022-09-28End: 2024-09-30Target: 24Updated: 2023-12-18